Mira Pharmaceuticals Steps Closer To Ketamir-2 IND Submission After Positive Preclinical Results
Pharmaceutical company MIRA Pharmaceuticals, Inc. (MIRA) said Tuesday it is conducting pre-clinical studies of Ketamir-2 in collaboration with Frontage Laboratories as a potential treatment for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD).
Source: rttnews.com